8th Pediatrics – Presentations

  Session 1: Pediatric HIV Treatment and Prevention: Getting to 90-90-90
  Chair: Elaine Abrams
 
Pediatric HIV Treatment and Prevention: From Then to Now
Dr. P. Mugyenyi, JCRC, Uganda
  Path to the Future: New Guidelines, New Drugs, New Strategies
 
Pediatric Drug Pipeline: New Drugs, New Strategies
Dr. M. Penazzato, WHO, Switzerland
 
New WHO Guidelines on Breastfeeding
Dr. N. Rollins, WHO, Switzerland
 
UNICEF Consultation: Countries Implementation of B+ (Pending)
Dr. C. Luo, UNICEF, USA
 
Testing at Birth – Update from South Africa
Dr. G. Sherman, U.Witwatersrand, South Africa
  Treatment cascade of HIV-infected infants in Thailand National Program: how close are we to the 90-90-90 target?
Dr. T. Puthanakit
  Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIV-infected Asian children stable on first-line cART
Dr. T. Sudjaritruk
  Virological response and resistance among HIV-infected children on first-line antiretroviral therapy without routine virological monitoring
Dr. A. Prendergast
  Session 2: Pediatric Antiretroviral Therapy
  Chair: George Sibery
 
CASE PRESENTATION
Dr. A. Moherndran, King Edward VIII Hospital, South Africa
 
CASE PRESENTATION
Dr. G. Tudor-Williams, 0, UK
  Access to antiretroviral initiation among HIV-infected children aged 0-19 years in the International Epidemiologic Databases to Evaluate AIDS Global Network
Dr. V. Leroy
  Switching to second-line antiretroviral therapy in HIV-infected children: a CIPHER cohort collaboration global analysis
Dr. R. Goodall
  Raltegravir (RAL) pharmacokinetics (PK) and safety in HIV-1-exposed neonates at high risk of infection (IMPAACT 1110)
Dr. D. Clarke
  HIV PCR testing at birth in KwaZulu Natal, South Africa – one year post introduction of the largest neonatal HIV testing programme
Dr. F. Moyo
  Paediatric HIV point of care testing: field evaluation of the performance of Cepheid and Alere qualitative HIV assays in a Soweto academic hospital
Dr. T. Murray
  Session 3: Adolescent Transition to Adult Care:
  What Do We Know and What Are the Research Priorities

  Chair: Annette Sohn
 
High-Resource Perspective on Adolescent Transition and Research Priorities
Dr. A. Judd, University College London, UK
 
Low-Resource Perspective on Adolescent Transition and Research Priorities 
(Pending)
Dr. M.A. Davies, University of Cape Town, South Africa
  The global epidemiology of perinatally HIV-infected adolescents: A CIPHER Global Cohort Collaboration analysis
Dr. A. Slogrove
  What does adolescent transition mean in sub-Saharan Africa? Predictors of transfer in Southern African perinatally HIV-infected adolescents (Pending)
Dr. M.A. Davies
  Session 4: Managing Children and Youth with HIV
  Chair: Jason Brophy
 
It’s Not Just HIV: Complications and Research Priorities in Care of HIV-Infected Youth
Dr. R. Ferrand, London School of Hygiene and Tropical Medicine, UK
  Higher retention and viral suppression rates in dedicated adolescent-friendly HIV clinic in South Africa
Dr. B. Zanoni
  Decreased bone turnover in HIV-infected children on antiretroviral therapy
Dr. S. Shiau
  Efficacy of the Amagugu intervention to increase maternal HIV disclosure to HIV-uninfected primary school aged children in Southern Africa: a randomized controlled trial (NOT AVAILABLE)
Dr. T.J. Rochat
  Session 5: Optimizing Diagnosis of HIV Infection in Infants and Children
  Chair: Tsungai Chipato
  Comparing Point of Care to Laboratory HIV PCR testing at birth in a hospital setting in Johannesburg, South Africa (NOT AVAILABLE)
Dr. K.G. Technau
  Does HIV DNA-PCR testing of HIV-exposed infants at birth reduce follow-up for routine testing at 4-14 weeks of age?
Dr. E. Kalk
  Impact of birth HIV PCR testing on routine 6-week EID testing in Cape Town, South Africa
Dr. L. Dunning
  Where have all the children gone? High HIV prevalence in infants attending nutrition and inpatient wards
Dr. C. Kiyaga
  Debate: PrEP Should Be Offered to All Sexually Active Adolescents for Prevention
  Chair: Diana Gibb
 
Debate: PrEP Should Be Offered to All Sexually Active Adolescents for Prevention PRO (Pending)
Dr. L.G. Bekker, Desmond Tutu HIV Foundation, South Africa
 
Debate: PrEP Should Be Offered to All Sexually Active Adolescents for Prevention CON
Dr. L. Mofenson, Elizabeth Glaser Pediatric AIDS Foundation, USA
  Session 6: Prevent of Mother-To-Child-Transmission in the Treatment Era
  Chair: Daya Moodley
 
Option B+: Beyond ART – Experience with Retention and Outcomes
Dr. L. Myer, University of Cape Town, South Africa
  Maternal Triple Antiretrovirals (mART) and Infant Nevirapine (iNVP) Prophylaxis for the Prevention of Mother-to-Child Transmission (MTCT) of HIV during Breastfeeding (BF) (NOT AVAILABLE)
Dr. T. Taha
  Outcomes of HIV-exposed infants before and after implementing Option B+ PMTCT guidelines in Kampala, Uganda: a retrospective cohort study
Dr. P. Elyanu
  Impact of tenofovir-containing triple antiretroviral therapy (ART) on bone mineral density in HIV-infected breastfeeding women in sub-Saharan Africa
Dr. L. Stranix
  Session 7: Coinfections and Complications of HIV in Children
  Chair: Mark Cotton
 
The Challenge of Drug-Resistant TB in Children with HIV
Dr. S. Schaaf, Tygerberg Children’s Hospital, South Africa
  Lung function in HIV-infected South African adolesents on antiretroviral therapy: the Cape Town adolescent antiretroviral cohort
Dr. L. Githinji
  Long-term neurodevelopmental outcomes on early limited or deferred continuous antiretroviral therapy: evidence from the CHER trial (NOT AVAILABLE)
Dr. B. Laughton
  Neuropsychological performance in African HIV children in a multi-site ARV clinical trial is poorer than non-infected children
Dr. M. Boivin
  Session 8: Joint Session HIV Pediatric Workshop and HIV Cure Workshop:
  Towards an HIV Cure in Children

  Chair: Deborah Persaud
 Neonatal and Pediatric Immunology Relevant to HIV Persistence
Nigel Klein, MRCP, PhD, University College London, UK
Deena Gibbons, Kings College London, UK